Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

1440 - Phase II study of resection of primary colorectal cancer and synchronous liver metastasis after S-1 + oxaliplatin (SOX) + Bevacizumab(Bmab) therapy and adjuvant S-1 chemotherapy

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Surgical Oncology

Tumour Site

Colon and Rectal Cancer

Presenters

Takuya Miura

Citation

Annals of Oncology (2018) 29 (suppl_8): viii150-viii204. 10.1093/annonc/mdy281

Authors

T. Miura, H. Morohashi, Y. Sakamoto, T. Yoshida, K. Sato, K. Ishido, D. Kudo, N. Kimura, K. Hakamada

Author affiliations

  • Gastroenterological Surgery, Hirosaki University Hospital, 036-8562 - Hirosaki/JP
More

Resources

Abstract 1440

Background

For resectable colorectal liver metastasis, perioperative adjuvant chemotherapy was suggested to prolong disease-free survival. However, the relapse rate was still high even after doublet therapy. To decrease the relapse rate, doublet + targetted therapy was tried but the efficacy and perioperative safety of the targetted therapy have not been significantly shown. These failures might be caused by inappropriate indication, timing of preoperative chemotherapy and short interval between chemotherapy and surgery. In these circumstances, we designed a preoperative doublet + bevacizumab therapy in high-risk patients such as synchronous liver metastasis before simultaneous resection of primary and liver metastasis.

Trial design

Primary end point: Disease-free survival. Inclusion criteria: 1. Clinical any T and any N with only liver metastases. Exclusion criteria: 1. Over 75 years old. 2. The patients had thromboembolism or significant abnormal electrocardiogram or cardiovascular disease. Protocol: S-1 is administered orally at 80mg/m2/day for 14 consecutive days followed by a 7-day rest. Oxaliplatin (L-OHP) was given intravenously on days 1, at a dose of 130mg/m2/day. Bevacizumab is given intravenously on days 1, at a dose of 7.5mg/kg/day. 21 days were assumed 1 course, and chemotherapy consisted of 4 courses. Surgery was carried out 8 to 12 weeks after the end of chemotherapy. Adjuvant chemotherapy of S-1 at 80mg/m2/day for 14 consecutive days followed by a 7-day rest was initiated within 6-8 weeks after surgery. Target sample: 28 patients. Features of this trial: Paying attention to the safety and efficacy of bevacizumab compared with prior trials according to the following points; 1. Long interval between surgery and the administration of bevacizumab. 2. Preoperative chemotherapy was administered prior to resection of primary colorectal cancer in order to increase the intensity of chemotherapy. 3. The loop ostomy is required before neoadjuvant chemotherapy in case of stenosis.

Clinical trial identification

UMIN000032102, release date: 2018/04/04.

Legal entity responsible for the study

Aomori Colorectal Cancer Study (ACCS) Group.

Funding

Has not received any funding.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.